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Editorial
In addition to two original research articles this issue of TCRM contains some excellent 
reviews on diverse clinical areas including control of chronic pain, Parkinson’s disease 
and the use of a novel biologic to treat chronic plaque psoriasis. Nersesyan and Slavin 
(2007) have provided a comprehensive overview of the problem of providing adequate 
analgesia for cancer patients. Indeed they point out that in the US alone 70% of people 
with cancer experience some degree of pain and that this inevitably intensiﬁ  es as the 
disease progresses. Regrettably less then half of these patents are given adequate 
pain relief giving rise to signiﬁ  cant suffering; of these around 25% actually die in 
pain. This is despite of the availability of several practice guidelines for cancer pain 
management of which the most widely used is the 3-step analgesic ladder developed 
by the World Health Organization. The authors propose that in a signiﬁ  cant number 
of cancer patients, particularly in those with neuropathic pain or pain associated with 
bone involvement, a more sophisticated 5-step algorithm might be required. In addition 
the authors have provided a comprehensive review of cancer pain assessment and 
its pharmacological or surgery-related management. The authors conclude with the 
recommendation that the control of cancer-related pain should be individualized for 
each patient and should include periodical re-evaluation of the medication regimen to 
ensure adequate analgesia and to minimize exposure to potentially dangerous adverse 
effects.
In contrast noncancer related chronic pain is most often associated with patients 
with lower back pain, myofacial pain or osteoarthritis thereby signiﬁ  cantly reducing 
quality of life together with considerable economic costs. In his timely review Bill 
McCarberg (2007) considers current treatment guidelines for the management of 
chronic pain and reviews the use of an extended-release formulation of tramadol. 
Tramadol is a centrally acting oral analgesic that acts through opioid receptor binding 
and inhibition of norepinephrine and serotonin reuptake. It is currently recommended 
as an alternative for patients unresponsive to or intolerant of nonselective NSAIDs and 
COX-2 inhibitors. The review focuses on the pharmacokinetics, safety and efﬁ  cacy 
of extended-release tramadol in the control of moderate to moderately severe pain in 
adults requiring treatment over an extended time period. The author concludes that 
extended release tramadol has beneﬁ  ts that may merit its earlier use in the treatment 
of moderate to moderately severe chronic pain.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that affects 
1%–2% of adults over the age of 60. However, the number of affected people may be 
much higher because of the initial asymptomatic progression of the disease—60% of 
the dopaminergic neuron population in the CNS having already degenerated before the 
appearance of symptoms. PD is generally regarded as a dopamine deﬁ  ciency disorder. 
The available therapeutic strategies mainly elevate the reduced levels of dopamine by 
utilizing different pharmacological mechanisms. However, none of these agents retards 
the progressive neurodegeneration associated with PD. Shimon Lecht and colleagues 
(2007) review the current treatment strategies for PD treatment with an emphasis on 
rasagiline, a novel selective and irreversible ropargylamine inhibitor of monoamnine 
oxidase B. It seems that this approach increases endogenous content of dopamine 
resulting in the reduction of PD symptoms. Unlike the prototypic monoamnine oxidase 
inhibitor selegiline; rasagiline is not metabolized to potentially toxic amphetamines. Therapeutics and Clinical Risk Management 2007:3(3) 362
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Interestingly there is evidence that rasagiline and other 
propargylamines derivatives exhibit neuroprotective effects 
in different neuronal models of PD and this property appears 
to be independent of monoamnine oxidase B inhibition. The 
authors ﬁ  nish by emphasizing the need to further elucidate the 
pharmacological mechanism of action of propargylamines in 
order to gain better insight into neuroprotective pathways to 
permit identiﬁ  cation of new pharmacological targets for the 
development of novel anti-PD drugs.
The chronic inﬂ  ammatory skin disorder psoriasis is a sig-
niﬁ  cant problem affecting up to 2% of the global population 
with approximately 30% of patients suffering from psoriatic 
arthritis. The condition exhibits a spectrum of symptoms 
with milder forms controlled by topical skin treatment while 
therapy for moderate to severe forms consists of treatments 
associated with signiﬁ  cant side effects. Psoriasis is an inﬂ  am-
matory autoimmune disease driven by inappropriate T cell 
activation. T cell activation requires a dual signal in which 
antigen presenting cells present antigen in association with 
the major histocompatibility class complex to the T cell 
receptor. Activation requires costimulatory signals which 
can be mediated by bridging of the lymphocyte function 
antigen (LFA)-3 on antigen presenting cells and CD2 on 
T cells. Alefacept is a novel dimeric human fusion protein 
consisting of the extracellular portion of the human LFA-3 
fused to the Fc portion of immunoglobulin G. This construct 
effectively blocks the interaction between LFA-3 and CD2 
thereby inhibiting the activation and proliferation of T cells. 
Jenneck and Novak (2007) have provided an interesting 
review on alefacep in the treatment of chronic plaque 
psoriasis. The authors report that alefacept represents a 
safe alternative therapeutic option for the treatment of 
patients with moderate to severe chronic plaque psoriasis 
with contraindications or resistance to traditional systemic 
therapies. However, they acknowledge limitations for the use 
of alefacept such as cost and the fact that a signiﬁ  cant number 
of patients do not respond to treatment. The latter problem is 
compounded by the fact that several months of treatment are 
required before nonresponders can be identiﬁ  ed. Moreover 
CD4+ T cells are essential for normal immune responses; thus 
effective therapy requires monitoring of lymphocytes counts 
in addition to evaluation of potential signs of infections or 
malignancies during treatment with alefacept.
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